BackContineum Therapeutics Overview

Contineum Therapeutics Long Term Debt

Track Contineum Therapeutics's long-term debt ($4.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$4.18M
51.20% YoYΔ $-4.39M vs prior year quarter

Peer trimmed avg / median

Loading

Contineum Therapeutics Long Term Debt History

Loading

Contineum Therapeutics vs. peers: Long Term Debt Comparison

Loading

Contineum Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Contineum Therapeutics (CTNM) FAQ

As of the most recent data (June 2026), CTNM shows a long-term debt of $4.2M. That compares with $8.6M in the prior-year period — down 51.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CTNM's long-term debt is now $4.2M (was $8.6M) — a 51.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Contineum Therapeutics is outperforming or lagging.

Tracking CTNM's long-term debt over time shows whether Contineum Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $4.2M That compares with $8.6M in the prior-year period — down 51.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Contineum Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $4.2M) with ownership activity and broader fundamentals.